Abstract
Anti-Tat therapeutic vaccination has been clinically investigated by different groups [1-4], given that 1) extracellular Tat protein induces T cell apoptosis and cellular immune suppression, 2) epidemiological data showed that LTNP exhibit high level of serum anti-Tat Ab, negatively correlated with p24 antigenemia, 3) in Tat immunized macaques, viremia decreased following SHIV challenge. Anti-Tat therapeutic vaccination using Tat Toxoid adjuvanted either with Seppic [1,2] or with alum or DcChol (Aventis Pasteur) proved to be safe. A prospective structured treatment interruption study (STI) monitored according to EU guidelines was conducted at Hospital St-Pierre, Brussels (Pr. N. Clumeck) on 31 vaccinees who received a DcChol adjuvanted Tat Toxoid (n = 12), a DcChol placebo (n = 8) or non adjuvanted Tat toxoid (n = 11). The 2 year study follow-up showed that vaccinees developing high titer of Abs neutralizing Tat bioactivity prolonged HAART-interruption.
Highlights
Nathan Clumeck1, Philippe Hermans*1, Daniel Zagury2, Hélène Le Buanec2, Arsène Burny3, Bernard Bizzini2, Bruce Gilliam4, Robert Redfield4 and Robert Gallo4
A single PDF containing all abstracts in this Supplement is available here http://www.biomedcentral.com/content/pdf/1742-4690-3-S1-info.pdf
Anti-Tat therapeutic vaccination has been clinically investigated by different groups [1-4], given that 1) extracellular Tat protein induces T cell apoptosis and cellular immune suppression, 2) epidemiological data showed that LTNP exhibit high level of serum anti-Tat Ab, negatively correlated with p24 antigenemia, 3) in Tat immunized macaques, viremia decreased following SHIV challenge
Summary
Nathan Clumeck1, Philippe Hermans*1, Daniel Zagury2, Hélène Le Buanec2, Arsène Burny3, Bernard Bizzini2, Bruce Gilliam4, Robert Redfield4 and Robert Gallo4. Address: 1Division of Infectious Diseases, CHU Saint-Pierre, Brussels, Belgium, 2Neovacs, S.A., 15, rue J-B. 75013 Paris, France, 3Laboratory of Experimental Hematology, Bordet Institute, 121 Blvd.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
